Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $29.00.

Several research analysts have recently weighed in on the company. The Goldman Sachs Group set a $24.00 target price on Kestra Medical Technologies in a report on Friday, January 16th. Piper Sandler raised their price objective on Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Wednesday, December 24th. Wells Fargo & Company increased their price target on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Finally, BTIG Research began coverage on Kestra Medical Technologies in a research report on Tuesday, November 18th. They set a “buy” rating and a $32.00 price objective for the company.

Kestra Medical Technologies Stock Down 2.0%

NASDAQ KMTS opened at $25.55 on Thursday. The business has a fifty day moving average price of $25.62 and a 200 day moving average price of $23.59. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.47 and a current ratio of 5.47. The company has a market cap of $1.49 billion and a P/E ratio of -8.06. Kestra Medical Technologies has a one year low of $13.25 and a one year high of $30.00.

Insider Activity at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $22.80, for a total transaction of $342,000.00. Following the transaction, the insider owned 394,786 shares of the company’s stock, valued at $9,001,120.80. The trade was a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Traci S. Umberger sold 10,500 shares of the company’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $26.69, for a total transaction of $280,245.00. Following the completion of the sale, the insider owned 136,633 shares of the company’s stock, valued at approximately $3,646,734.77. This trade represents a 7.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 40,500 shares of company stock valued at $1,021,095 in the last 90 days. Insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies in the fourth quarter valued at approximately $31,000. Russell Investments Group Ltd. increased its stake in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Kestra Medical Technologies during the third quarter worth $48,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Kestra Medical Technologies in the 2nd quarter valued at about $54,000. Finally, BNP Paribas Financial Markets raised its position in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.